Respiratory syncytial virus is common but it can be dangerous for some infants and young kids. Here's everything parents need ...

The Trump administration appears to be expanding RSV vaccinations to some adults starting at age 50 instead of 60 ...

The Food and Drug Administration has approved three vaccines for RSV — GSK's GSK.L Arexvy, Moderna's MRNA.O mRESVIA and ...

The new RSV recommendation calls for a single dose of vaccine for adults age 50 to 59 years who are at increased risk of ...

The expanded recommendation is good news for Moderna, Pfizer, and GSK, which all sell RSV vaccines for older adults. Moderna ...

The U.S. Centers for Disease Control and Prevention has accepted recommendations made by a panel of vaccine experts in April, ...

As Thailand transitions from the rainy to early winter seasons, respiratory infections surge dramatically, making awareness ...

The ACIP is recommending the use of Enflonsia for the prevention of RSV lower respiratory tract disease in infants younger than 8 months.

Two panel members still voted against it, however. RSV infects nearly everyone by the time they’re 2. It causes cold symptoms, affecting the breathing passages and lungs, according to the CDC.

RSV is ubiquitous, one of the most common causes of childhood illness. Most kids will catch this highly contagious respiratory virus at some point before they turn 2, according to the CDC.

Key takeaways: The FDA approved the monoclonal antibody clesrovimab-cfor for preventing RSV disease in babies. Unlike nirsevimab, which has weight-based dosing, clesrovimab has a fixed dose.

The Food and Drug Administration (FDA) has expanded the approval of mResvia (respiratory syncytial virus [RSV] vaccine) to include active immunization in individuals 18 through 59 years of age who ...